Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It is proposed that isocitrate dehydrogenase 1 (IDH1) mutation predicts the outcome in patients with high-grade glioma.
|
26316565 |
2015 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
|
26618343 |
2016 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patient 2, with malignant glioma with primitive neuroectodermal tumor (MGPNET), had a secondary GBM with a noncanonical isocitrate dehydrogenase 1 (IDH1) mutation and 11-year-survival; autopsy showed encasement of the entire bilateral ventricular system by SVS.
|
26308254 |
2016 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
|
22869205 |
2012 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Similarly, in human malignant gliomas harbouring IDH1 mutations, we find markedly elevated levels of 2HG.
|
19935646 |
2009 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the expression of Sox11 in 132 diffuse astrocytomas in relation to the regulator cell marker nestin, c-Met and IDH1-R132H, which have shown to be differentially expressed among the molecular subgroups of malignant gliomas, as well as to an inducer of astrocytic differentiation, that is, signal transducer and activator of transcription (p-STAT-3), clinicopathological features and survival.
|
23619925 |
2013 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase 1 gene (IDH1) R132H mutation status was also recently identified as a prognostic factor for malignant gliomas.
|
24929863 |
2014 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We present the case of a 28-year-old man with an IDH1 and TP53 mutant high grade glioma with abnormalities in chromosomes 1 and 19 suggestive of anaplastic oligodendroglioma that rapidly progressed to widespread metastatic disease.
|
30738431 |
2019 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polar spongioblastoma: A high-grade glioma that does not contain the IDH1 mutation or 1p/19q LOH.
|
20102524 |
2010 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identify miR148a as a novel, G-CIMP-associated miRNA whose methylation is tightly correlated with IDH1 mutation and associated with improved survival in patients with malignant glioma.
|
25224277 |
2014 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
• APT signals were significantly higher in IDH-wild type compared to IDH-mutant high-grade glioma.
|
31175415 |
2019 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent investigations of malignant gliomas have identified additional genetic and chromosomal abnormalities which cluster with IDH1 mutations into two distinct subgroups.
|
25471051 |
2015 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine the prognostic value of isocitrate dehydrogenase 1 (IDH1) mutation, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and 1p/19q co-deletion in Japanese patients with malignant gliomas.
|
24160898 |
2013 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are common in malignant gliomas in older children, suggesting that a subset of these lesions may be biologically similar to malignant gliomas arising in younger adults and may be associated with a more favorable prognosis.
|
20725730 |
2011 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
En bloc resection revealed a high-grade glioma with sarcomatous components that was immunoreactive for the R132H variant of IDH1 by antibody.
|
27153165 |
2017 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort.
|
23934175 |
2013 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PET with <sup>18</sup>F-GE-180 and <sup>18</sup>F-FET provides differing imaging information in HGG dependent on the IDH-mutational status, with diverging spatial overlap and vast exceedance of contrast-enhancement in MRI.
|
30244386 |
2019 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The NRF2 activity is increased in a significant proportion of malignant gliomas in general but decreased in the majority of IDH1/2-mutant anaplastic gliomas.
|
25304134 |
2015 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The interesting identification of an IDH1 mutation in a radiation-induced secondary malignant glioma raises the likelihood that these types of tumor may develop IDH1/2 mutations.
|
22821382 |
2012 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
|
19228619 |
2009 |
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results of this study suggest that IDH1 mutation may be associated with polySia expression pathways in malignant gliomas.
|
25164322 |
2014 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CMRO<sub>2</sub> showed the highest diagnostic performance for IDH gene mutation detection in low-grade glioma (AUC, 0.818) and MTI in high-grade glioma (AUC, 0.854) and for all WHO grades (AUC, 0.899) among all biomarkers.
|
27982759 |
2017 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most IDH-wildtype tumors showing histopathological and radiological features of low-grade diffuse astrocytoma exhibit molecular and clinical features of high-grade glioma and may represent an early stage of primary glioblastoma.
|
29444314 |
2018 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, mutations of the ATRX gene have been found in various subtypes and grades of gliomas and were shown to refine the prognosis of malignant gliomas in combination with IDH and 1p/19q status.
|
24559763 |
2014 |
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
|
26618343 |
2016 |